Tirzepatide makes people lose more weight than semaglutide. That's not in question. a 2026 meta-analysis of 12 studies showed tirzepatide users lost an extra 4.76 kg on average, with 1.5-2.8x higher odds of hitting the 10-20% weight loss milestones.
But here's the twist: in a real-world study of 10,625 patients with cardiovascular disease, semaglutide reduced heart attack and stroke risk by 29%, while tirzepatide didn't show the same protection. despite causing more weight loss.
More weight loss. Worse cardiovascular outcomes. How does that work?
The numbers on weight loss
Tirzepatide wins this round easily. In the SURMOUNT-1 trial, people on the highest dose lost 22.5% of their body weight over 72 weeks. If you weigh 100 kg, that's dropping to 77.5 kg. No weight loss drug has ever come close to that number.
Semaglutide users in comparable trials lost 15-17%. still excellent, but not tirzepatide-level.
A 2026 meta-analysis quantified the difference:
- Tirzepatide users lost 4.61% more body weight
- Absolute difference: 4.76 kg more weight lost
- 1.52-2.82x higher odds of hitting ≥10-20% weight loss targets
For pure weight loss, tirzepatide is the stronger drug. No debate.
The cardiovascular surprise
But when researchers looked at cardiovascular outcomes in patients with atherosclerotic cardiovascular disease (ASCVD), something unexpected showed up.
In a study of 10,625 matched patients:
- Semaglutide reduced major adverse cardiovascular events (MACE-3) by 29% (HR 0.71, p=0.046)
- Tirzepatide showed greater weight loss but worse CV risk reduction
- The benefit appeared within 2 months and was independent of how much weight people lost
That last point is key: the heart protection didn't come from the weight loss. It came from something else semaglutide does.
Why the difference matters
Both drugs are GLP-1 receptor agonists. But tirzepatide is also a GIP (glucose-dependent insulinotropic polypeptide) agonist. That dual action explains the extra weight loss.
But it might also explain why semaglutide has better cardiovascular effects. GLP-1 receptors exist in heart tissue and blood vessels. Semaglutide hits those receptors harder. Tirzepatide spreads its activity across two systems.
This is speculative. we don't have mechanistic proof yet. But the real-world data is consistent: semaglutide protects the heart better, even when it causes less weight loss.
What this means if you're choosing
If your primary goal is weight loss and you don't have cardiovascular disease, tirzepatide is probably the better bet. You'll lose more weight, and the side effect profiles are similar (nausea, GI issues).
If you have atherosclerotic cardiovascular disease. a history of heart attack, stroke, or significant arterial plaque. semaglutide might be the smarter choice. The weight loss will be less dramatic, but the heart protection could matter more.
There's also cost to consider. Both drugs are expensive, and insurance coverage varies. Semaglutide has been around longer, so it's sometimes easier to get approved.
The gaps in the research
This cardiovascular data comes from one large observational study, not a head-to-head randomized trial. Observational studies can miss confounding factors.
We also don't know if tirzepatide would show better CV outcomes in a different population. The study looked at people with ASCVD and overweight/obesity but without diabetes. Maybe in diabetic patients, the results flip.
And we have no long-term data on either drug beyond a few years. We don't know if these benefits persist, fade, or grow over a decade of use.
The bigger picture
The lesson here: more isn't always better. Tirzepatide causes more weight loss, but that doesn't automatically translate to better health outcomes across the board.
Your heart doesn't care how much you weigh as much as it cares about inflammation, endothelial function, and metabolic stability. Semaglutide seems to address those things more directly.
This is why you need a doctor who understands your full risk profile, not just your BMI.
Takeaways
- Tirzepatide causes 4.76 kg more weight loss on average vs semaglutide
- Semaglutide reduces cardiovascular events by 29% in real-world data, independent of weight loss
- The dual GLP-1/GIP action in tirzepatide drives more weight loss but may dilute cardiovascular protection
- If you have ASCVD, semaglutide might be the safer choice; for pure weight loss, tirzepatide wins
- We need long-term randomized trials to settle this properly
This is educational content, not medical advice. Talk to your doctor before starting any GLP-1 agonist.